Acumen Pharmaceuticals (ABOS) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pluri (PLUR) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 75.3% versus a loss of 88.1%. Over five years, PLUR leads with a -95.6% price change compared with -97.7% for ABOS. Pluri is the larger company by market cap ($13.5 million vs $13.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | PLUR |
|---|---|---|
| Share price | $0.1865 | $0.94 |
| Market cap | $13.49M | $13.51M |
| 1-day change | -3.52% | -3.07% |
| YTD return | -91.16% | -68.56% |
| 1-year return | -88.12% | -75.26% |
| 5-year return | -97.74% | -95.63% |
| EPS (TTM) | $-1.55 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.02M |
| Revenue growth (YoY) | — | -23.95% |
| Net income (latest FY) | $-121.33M | $-23.82M |
| Gross margin | — | 44.59% |
| Operating margin | — | -2454.53% |
| Net margin | — | -2344.59% |
| 52-week high | $3.60 | $3.94 |
| 52-week low | $0.16 | $0.85 |
| Distance from 52-week high | -94.82% | -76.14% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +3975.07% | — |
| Average volume | 2.73M | 36.98K |
| Shares outstanding | 72.33M | 14.38M |
| Employees | 60 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLUR has outperformed ABOS by 12.9 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
ABOS vs PLUR FAQ
Which is bigger, Acumen Pharmaceuticals or Pluri?
Pluri (PLUR) is larger, with a market capitalization of $13.51M compared with $13.49M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or PLUR?
PLUR returned -75.26% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Pluri in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.